EuroEyes International Eye Clinic Limited Fundamental Analysis (HKSE: 1846.HK)
EuroEyes International Eye Clinic Limited Fundamental Analysis (HKSE: 1846.HK)
EuroEyes International Eye Clinic Limited (HKSE: 1846.HK) shows weak financial fundamentals with a PE ratio of 301.95, profit margin of 0.28%, and ROE of 0.20%. The company generates $0.9B in annual revenue with strong year-over-year growth of 11.23%.
Key Strengths
Areas of Concern
The stock receives a Fundamental Health Score of 39.1/100 based on profitability, valuation, growth, and balance sheet metrics. The F grade reflects weak fundamentals and significant financial concerns.
Fundamental Health Score
We analyze 1846.HK's fundamental strength across five key dimensions:
Efficiency Score
Weak1846.HK struggles to generate sufficient returns from assets.
Valuation Score
Moderate1846.HK shows balanced valuation metrics.
Growth Score
Moderate1846.HK shows steady but slowing expansion.
Financial Health Score
Excellent1846.HK maintains a strong and stable balance sheet.
Profitability Score
Moderate1846.HK maintains healthy but balanced margins.
Key Financial Metrics
Is 1846.HK Expensive or Cheap?
P/E Ratio
1846.HK trades at 301.95 times earnings. This suggests a premium valuation.
PEG Ratio
When adjusting for growth, 1846.HK's PEG of -3.12 indicates potential undervaluation.
Price to Book
The market values EuroEyes International Eye Clinic Limited at 0.61 times its book value. This may indicate undervaluation.
EV/EBITDA
Enterprise value stands at 6.41 times EBITDA. This is generally considered low.
How Well Does 1846.HK Make Money?
Net Profit Margin
For every $100 in sales, EuroEyes International Eye Clinic Limited keeps $0.28 as profit after all expenses.
Operating Margin
Core operations generate 5.46 in profit for every $100 in revenue, before interest and taxes.
ROE
Management delivers $0.20 in profit for every $100 of shareholder equity.
ROA
EuroEyes International Eye Clinic Limited generates $0.14 in profit for every $100 in assets, demonstrating efficient asset deployment.
Following the Money - Real Cash Generation
Operating Cash Flow
EuroEyes International Eye Clinic Limited produces operating cash flow of $183.56M, showing steady but balanced cash generation.
Free Cash Flow
EuroEyes International Eye Clinic Limited generates strong free cash flow of $139.00M, providing ample flexibility for dividends, buybacks, or growth.
FCF Per Share
Each share generates $0.44 in free cash annually.
FCF Yield
1846.HK converts 18.67% of its market value into free cash.
Financial Ratios Analysis
Valuation Ratios
P/E Ratio
Price to earnings ratio
301.95
vs 25 benchmark
PEG Ratio
Price/earnings to growth ratio
-3.12
vs 25 benchmark
P/B Ratio
Price to book value ratio
0.61
vs 25 benchmark
P/S Ratio
Price to sales ratio
0.85
vs 25 benchmark
Financial Health
Debt/Equity
Total debt to shareholders' equity
0.32
vs 25 benchmark
Current Ratio
Current assets to current liabilities
3.13
vs 25 benchmark
Efficiency Ratios
ROE
Return on equity percentage
0.002
vs 25 benchmark
ROA
Return on assets percentage
0.001
vs 25 benchmark
ROCE
Return on capital employed
0.03
vs 25 benchmark
How 1846.HK Stacks Against Its Sector Peers
| Metric | 1846.HK Value | Sector Average | Performance |
|---|---|---|---|
| P/E Ratio | 301.95 | 31.31 | Worse (Expensive) |
| ROE | 0.20% | 526.00% | Weak |
| Net Margin | 0.28% | 21528.00% | Weak |
| Debt/Equity | 0.32 | 0.53 | Strong (Low Leverage) |
| Current Ratio | 3.13 | 5.62 | Strong Liquidity |
| ROA | 0.14% | -105.00% (disorted) | Weak |
1846.HK outperforms its industry in 2 out of 6 key metrics, but lagging in P/E Ratio.
Historical Growth Performance
5-Year Growth Trajectory
This section reviews EuroEyes International Eye Clinic Limited's 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.
Revenue CAGR
97.34%
Industry Style: Defensive, Growth, Innovation
High GrowthEPS CAGR
-2.48%
Industry Style: Defensive, Growth, Innovation
DecliningFCF CAGR
190.07%
Industry Style: Defensive, Growth, Innovation
High Growth